Healthcare Industry News: neuromodulation
News Release - August 10, 2017
NeoSync Secures $13 Million in Financing with Valiance Life Science Investments and Current InvestorsAdditional investment will help fund the company's planned registration study of NESTŪ Technology in patients with Treatment Resistant Depression (TRD).
BOSTON, Aug. 10, 2017 -- (Healthcare Sales & Marketing Network) -- NeoSync, Inc., a clinical-stage company with a proprietary platform technology being used to develop advanced, non-invasive neuromodulation products, announced today the completion of its Series D financing round, which included investment from Valiance Life Science Investments, as well as its original investor base totaling $13 million.
NeoSync plans to use the proceeds from this latest financing round to fund a registration trial using their proprietary NESTŪ technology in Treatment Resistant Depression. The investment will also accelerate the company's efforts to prepare for future commercial release of this novel technology.
"This latest round of funding will allow us to execute remaining activities needed to gain regulatory clearance for our novel device," said Kate Rumrill, President and CEO of NeoSync. "We believe, once commercially available, our device will open up broader access to TMS, in a more convenient environment for patients."
"With its unique and innovative NESTŪ technology, NeoSync is well positioned to change the way TMS treatment is perceived and delivered," said Jan Pensaert, founder and CEO of Valiance. "A home-use device is a very compelling proposition for patients suffering from depression and we are delighted to support NeoSync's management team in their efforts to make their device a clinical and commercial success."
About NESTŪ sTMS Technology
NESTŪ (NeoSync-EEG Synchronized TMS) delivers low energy, alternating magnetic field stimulation in daily 30 minute sessions to gently adjust a depressed brain toward a more normal state. Unique among TMS therapies, synchronized TMS (sTMS) used by NESTŪ is personalized to a patient's individual alpha brain frequency, as measured by a brief electroencephalogram (EEG) recording. NeoSync's patented device design and configuration provides a unique ability to bring TMS therapy to a broader patient population with an at-home treatment option, under the care of their physician.
About NeoSync, Inc.
NeoSync is a clinical-stage company pioneering personalized transcranial magnetic stimulation for the treatment of Major Depressive Disorder and other diseases of the Central Nervous System (CNS). With their proprietary platform technology they are well-positioned to unlock the enormous potential of an existing but still nascent market, with a disruptive home use design. The Company is led by experienced medical device executives and entrepreneurs. Headquartered in Boston, MA, NeoSync is privately held.
Valiance is a specialist growth capital investment firm based in London, backing serial entrepreneurs with excellent track records and assisting them through the growth stages of their businesses towards an exit. Valiance is authorized and regulated by the UK Financial Conduct Authority and Guernsey Financial Services Commission.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.